Overview

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Status:
Completed
Trial end date:
2019-03-15
Target enrollment:
Participant gender:
Summary
- Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborator:
Astellas Pharma Global Development, Inc.
Treatments:
Erlotinib Hydrochloride
Mitogens